AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.300
-0.050 (-1.15%)
At close: Aug 28, 2025, 4:00 PM
4.310
+0.010 (0.23%)
After-hours: Aug 28, 2025, 4:16 PM EDT

AbCellera Biologics Operating Metrics

Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Number of Discovery Partners
-----46.0042.0041.0041.0040.0038.0038.0036.00
Number of Discovery Partners Growth
-----15.00%10.53%7.89%13.89%11.11%8.57%15.15%24.14%
Number of Molecules in the Clinic
16.0016.0014.0014.0013.0013.0010.009.00-
Number of Molecules in the Clinic Growth
23.08%23.08%40.00%55.56%44.44%62.50%42.86%50.00%-
Partnered Program Starts
-----404.00392.00374.00356.00339.00342.00319.00291.00
Partnered Program Starts Growth
-----19.17%14.62%17.24%22.34%29.89%45.53%47.00%41.95%
Programs Under Contract
-----203.00182.00177.00177.00174.00164.00164.00158.00
Programs Under Contract Growth
-----16.67%10.98%7.93%12.03%11.54%5.81%18.84%32.77%
Period EndingMar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Royalty
---------443.03M568.07M474.94M462.87M327.35M391.16M---
Royalty Growth
---------35.34%45.23%-------
Research Fees
20.58M26.28M30.26M30.38M34.76M35.56M38.24M39.33M
Research Fees Growth
-40.80%-26.08%-20.86%-22.75%-17.31%-12.86%12.04%23.89%
Milestone Payments
---3.50M-2.40M--3.15M8.90M16.40M----21.00M23.00M-
Milestone Payments Growth
----78.66%--88.57%---86.30%---------
Licensing
1.04M1.05M953.00K921.00K777.00K969.00K948.00K916.00K----
Licensing Growth
33.33%8.26%0.53%0.55%-7.17%39.22%58.53%44.48%----
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.